Pipra
Z├╝rich
About Pipra
Delirium is one of the largest issues in healthcare and is massively unaddressed. It represents a significantly higher cost than diabetes. Post-Operative Delirium (POD) is the most common post-surgical complication affecting 20% of patients over 60 with long-term consequences for patients and enormous costs to hospitals and insurers. Our CE-certified, A.I-driven clinical decision support software helps doctors identify high-risk patients prior to surgery. Highlighting high-risk patients allows for effective, cost-reducing measures to be implemented shown to decrease the incidence by 53%. We are currently live in 3 hospitals with 22 hospitals throughout Europe in our pipeline. Our advisory board includes 6 KOL’s from aroudn the world including in the U.S. from Johns Hopkins, Harvard and Cornell.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $3.9M
- Funding stage: Seed
- Last round: Seed (Jan 2023)
- Website: pipra.ch
- Phone: +41 78 621 27 77
Industries & Categories
Health Care, Medical, Medical Device, Software
Social Profiles
Canonical: https://fsome.com/organization/pipra-121160 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.